Press releases

Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections...

DEINOVE (Euronext Growth Paris: ALDEI), a French biotech company that uses a disruptive approach to develop innovative antibiotics and bio-...

Finalization of the acquisition of DNV3837, a promising antibiotic for treating severe gastrointestinal infections caused by Clostridium...

The equity line funding set up in December 2014 expired. It has enabled DEINOVE to raise €9.4 million net in a flexible, optimized manner...

Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia and Japan. The...

The General Meeting approved the contribution in kind of the BIOVERTIS (parent company of MORPHOCHEM) shares and options and the issuance...

MORPHOCHEM's MCB3837 antibiotic compound aims to treat severe gastrointestinal infections caused by Clostridium difficile , a priority...

Acceleration of the Antibiotics program: €14.6m of funding by Bpifrance (including € 10.4m for the DEINOVE Group) and structuring of the...

Cash position: +€6.6m at June 30, 2017 compared to +€9.3m at December 31, 2016. Half-year net loss of DEINOVE Group (composed of DEINOVE...